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ABSTRACT 41 
Hepatitis B virus (HBV) is a major cause of liver diseases including hepatocellular carcinoma 42 
(HCC), and more than 650,000 people die annually due to HBV-associated liver failure. Extensive 43 
studies of individual promoters have revealed that heterogeneous RNA 5’-ends contribute to the 44 
complexity of HBV transcriptome and proteome. Here we provide a comprehensive map of HBV 45 
transcription start sites (TSSs) in human liver, HCC and blood, as well as several experimental 46 
replication systems, at single nucleotide resolution. Using CAGE analysis of 16 HCC/non-tumor liver 47 
pairs, we identify 17 robust TSSs, including a novel promoter for the X gene located in the middle of 48 
the gene body, which potentially produces a shorter X protein translated from the conserved second 49 
start codon, and two minor anti-sense transcripts that might represent viral ncRNAs. Interestingly, 50 
transcription profiles were similar in HCC and non-tumor livers, although quantitative analysis 51 
revealed highly variable patterns of TSS usage among clinical samples, reflecting precise regulation 52 
of HBV transcription initiation at each promoter. Unlike the variety of TSSs found in liver and HCC, 53 
the vast majority of transcripts detected in HBV-positive blood samples are pgRNA, most likely 54 
generated and released from liver. Our quantitative TSS mapping using the CAGE technology will 55 
allow better understanding of HBV transcriptional responses in further studies aimed at eradicating 56 
HBV in chronic carriers. 57 
 58 
IMPORTANCE 59 
Despite the availability of a safe and effective vaccine, HBV infection remains a global health 60 
problem, and current antiviral protocols are not able to eliminate the virus in chronic carriers. 61 
Previous studies of the regulation of HBV transcription have described four major promoters and two 62 
enhancers, but little is known about their activity in human livers and HCC. We deeply sequenced the 63 
HBV RNA 5’ends in clinical human samples and experimental models by using a new, sensitive and 64 
quantitative method termed cap analysis of gene expression (CAGE). Our data provide the first 65 
comprehensive map of global TSS distribution over the entire HBV genome in the human liver, 66 
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validating already known promoters and identifying novel locations. Better knowledge of HBV 67 
transcriptional activity in the clinical setting has critical implications in the evaluation of therapeutic 68 
approaches that target HBV replication. 69 
70 
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INTRODUCTION 71 
Hepatitis B virus (HBV) is a major etiological agent of acute and chronic liver diseases 72 
including hepatocellular carcinoma (HCC), the second leading cause of cancer mortality worldwide (1, 73 
2). About 240 million people are estimated to be chronically infected by HBV, and more than 650,000 74 
people die annually due to HBV-associated liver failure (3). HBV is the prototype member of the 75 
hepadnavirus family, characterized by a compact DNA genome replicating with its own reverse 76 
transcriptase from an RNA intermediate (4). This virus is classified into 8 major genotypes with 77 
distinct geographic distribution (5, 6).  The HBV genome carries four open reading frames (ORFs), 78 
which encode seven different proteins including three surface proteins, the core and e antigens, the 79 
polymerase and the X transactivator. The expression of these genes is regulated by four promoters and 80 
two enhancers, which direct the production of six distinct mRNAs (two 3.5 kb transcripts for the core 81 
and e antigens, the polymerase and for pregenomic (pg) RNA, one 2.4 kb transcript for the large 82 
surface protein (LHBs), two 2.1 kb transcripts for the middle and small surface proteins (MHBs and 83 
SHBs), and one 0.7 kb mRNA for the X transactivator protein (7-9). Heterogeneous 5’-ends and in-84 
frame ATG codons play important roles in increasing the diversity of proteins made from a small 85 
genome. For example, two 3.5 kb mRNAs are transcribed from the core promoter with slightly 86 
different transcription start sites (TSSs); one containing the preC start codon is named precore mRNA, 87 
translated into the precore protein and giving rise to the e antigen, and the other missing this start 88 
codon is called pregenomic RNA (pgRNA), which is translated into the core and polymerase proteins 89 
as well as it serves as a template for viral DNA replication (8, 10). In addition, two 2.1 kb mRNAs are 90 
transcribed from the S promoter with 5’ heterogeneity; one TSS containing the preS2 start codon is 91 
for MHBs, and the other downstream the preS2 start codon is for the SHBs (11). Exact positions of 92 
TSSs for individual promoters have been studied using 5’ RACE and RNase protection assay; 93 
however, how frequently each start site is used in different hosts and conditions is not well understood. 94 
In addition, analysis of the numerous TSSs in the HBV genome requires high-throughput technologies 95 
for comprehensive mapping in a quantitative manner. 96 
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Cap Analysis of Gene Expression (CAGE), a method for genome-wide identification of 97 
transcription start sites (TSSs), is focused on the selective capture of the capped 5’ ends of RNAs 98 
(cap-trapping). It is based on the principle that the cap site and 3’ end of mRNA are the only sites 99 
carrying the diol structure that can be chemically labelled with a biotin group. By using streptavidin-100 
coated magnetic beads, only the full-length first-strand cDNA/mRNA hybrids are selectively 101 
recovered after RNase I treatment. Sequencing short sequence reads (or tags) taken from the 5’ ends 102 
of full-length cDNAs allows TSSs to be mapped and their expression, measured by tag frequency, to 103 
be analyzed (12, 13). The CAGE technology has been extensively used to identify exact positions of 104 
TSSs in various different organisms from mammals to viruses (14-16). CAGE has also shown high 105 
reproducibility for expression measurements through a number of large scale projects including 106 
FANTOM (17, 18) and ENCODE (19), discovering novel ncRNAs and transcribed enhancers (20). 107 
Because the HBV genome is entirely coding, with extensive overlap of the viral genes, quantification 108 
of individual transcripts by RNA-Seq is not feasible. Here we used the CAGE technology for 109 
quantitative mapping of TSSs on the whole HBV genome at single-nucleotide-resolution. We 110 
analyzed the HBV transcriptome in chronically infected human livers and HCCs that we collected and 111 
sequenced in a previous study (21), in whole blood from HBV positive patients, as well as several 112 
experimental models of HBV replication. To our knowledge, our data provide the most 113 
comprehensive map of quantitative TSSs as a resource to study transcriptional activity of HBV in 114 
experimental setting, and design new therapeutic approaches for inhibiting HBV replication in 115 
chronically infected patients. 116 
 117 
MATERIALS AND METHODS 118 
 119 
CAGE libraries for human liver tissues 120 
CAGE libraries for human liver tissues were prepared and sequenced as detailed in our 121 
previous study (21). Raw data are available through the NCBI dbGaP database (22) under accession 122 
 o
n
 O
ctober 3, 2016 by INSTITUT PASTEUR-Bibliotheque
http://jvi.asm.org/
D
ow
nloaded from
 
6 
 
number phs000885.v1.p1 (controlled access). Briefly, liver tissues including tumor and non-tumor 123 
samples were collected from patients resected for HCC (Tables 1 and S1). CAGE libraries were 124 
prepared following published protocol (12) and sequenced with single-end reads of 50 bp on the 125 
Illumina HiSeq 2000 platform. The ethics evaluation committees of the INSERM (IRB00003888, 126 
FWA00005831) and RIKEN (H24-4) approved the use of human liver samples. All patients provided 127 
written informed consent. 128 
CAGE libraries for human blood and HBV model systems 129 
The ethics review committee of Saitama Medical University approved the use of human blood 130 
samples. Blood samples were collected from male HBV (genotype C) positive patients who did not 131 
develop HCC. Total RNA was extracted from RNAlaterR (Ambion)-treated whole blood using the 132 
RiboPureTM-Blood Kit (Ambion) followed by the RNeasy kit (Qiagen) for further purification. CAGE 133 
libraries were prepared following the latest version of the protocol, which does not require a PCR 134 
amplification step (13), and were sequenced with single-end reads of 50 bp on the Illumina HiSeq 135 
2000 platform. 136 
 137 
Determination of CAGE TSSs  138 
We mapped the CAGE tags to the human genome (hg19/GRCh37 assembly), or to the murine 139 
genome (mm9/NCBI37 assembly) in the case of the murine liver transduced with AAV-HBV, using 140 
BWA v0.5.9 (23) with default parameters on the MOIRAI pipeline (24). The unmapped tags extracted 141 
from the mapping results were aligned to 16 representative HBV genomes downloaded from HBVdb 142 
(25). Because the HBV genome is circular, each genome was tandemly repeated for mapping all 143 
genome sequences. After alignment of tag sequences with 16 representative HBV genomes, the HBV 144 
genotype in each sample was defined as the genome to which the highest tag counts were mapped. To 145 
unify the genomic positions of HBV, an HBV genome sequence (accession number GQ358158.1 in 146 
GenBank) with genotype C and genome size: 3,215 bp was selected as a reference genome. The 147 
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genomic positions for the other genomes were converted to those of the reference genome based on 148 
multiple alignments of HBV genomes. CAGE technology often adds an extra G base to the 5’ end in 149 
the reverse transcription process (26). To correct one base shift of the 5’ end, the first mismatched G 150 
was removed. We then clustered the tags to define distinct CAGE peaks using Paraclu with following 151 
parameters (i) a minimum of 100 total tags per cluster, (ii) minimum density increase of 2, and (iii) a 152 
maximal cluster length of 100bp (27). Paraclu was designed to identify CAGE TSS peaks and is 153 
commonly used in studies using CAGE such as ENCODE. The algorithm calculates densities of 154 
CAGE tags, and find maximal segments where every prefix and suffix of the segment has a given 155 
density. Raw tag counts for each peak were divided by a total tag count of the library including human 156 
transcriptome to calculate normalized expression values. The unit of the expression value is tpm, tags 157 
per mapped million tags. CAGE tags and peaks were visualized using IGV (28). 158 
Cells 159 
The HepAD38 cell line is derived from HepG2 cells and contains the HBV genome (subtype 160 
ayw) under tetracycline control (29). HepAD38 cells were maintained in DMEM/F-12 with 10% FCS, 161 
3.5 × 10–7 M hydrocortisone hemisuccinate, and 5 μg/ml insulin. Primary human hepatocytes (PHH) 162 
were purchased from Corning (Catalog Number 454541, Lot Number 399) and maintained in PHH 163 
medium (Corning catalog number 355056, Corning® Hepatocyte Culture Media Kit, 500mL) as 164 
recommended by the manufacturer. 165 
Virus production and infection of primary human hepatocytes 166 
For virus production, HepAD38 Cells were grown in Williams E medium with 5% FCS, 7 x 167 
10-5 M hydrocortisone hemisuccinate, 5μg/ml insulin and 2% DMSO. HBV particles were 168 
concentrated from the clarified supernatant by overnight precipitation with 5% PEG 8000 and 169 
centrifugation at 4°C for 60 min at 5000 rpm. Enveloped DNA-containing viral particles were tittered 170 
by immunoprecipitation with an anti-PreS1 antibody (kindly provided by C. Sureau) followed by 171 
qPCR quantification of viral RC DNA with the following primers: RC5', 5'-172 
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CACTCTATGGAAGGCGGGTA-3' and RC3', 5'-TGCTCCAGCTCCTACCTTGT-3' (30). Around 173 
20-25% of HBV DNA measured in the cell supernatant was recovered in the preS1 174 
immunoprecipitate, correlating with the finding of 25% of enveloped virions and 75% of naked 175 
capsids by using native agarose gel electrophoresis, transfer onto nitrocellulose and hybridization with 176 
radiolabeled HBV probe and anti-HBs antibody as previously described (31). For infection, only 177 
enveloped DNA-containing viral particles (vp) were taken into account to determine the multiplicity 178 
of infection (MOI). PHH were infected as previously described with normalized amounts of virus at a 179 
MOI of 500 vp/cell (32). 180 
Animal experiments 181 
The AAV-HBV vector has been described previously (33) Six-week-old FVB/NCrl male 182 
mice obtained from The Jackson Laboratory received a single tail vein injection of 5 x 1010 viral 183 
genomes (vg) of AAV-HBV vector or control vector AAV-GFP. Mice were sacrificed 20 weeks post-184 
injection. Total RNA was extracted from mouse livers with TRI Reagent (Sigma-Aldrich). The 185 
experimental procedures were approved by Institut Pasteur (N° CHSCT: 10.289), in accordance with 186 
the French government regulations. Mice were bred in a pathogen-free environment at the Institut 187 
Pasteur animal facility in accordance with welfare criteria outlined in the “Guide for the Care and Use 188 
of Laboratory Animals”.  189 
Northern blot analysis 190 
Twenty µg of total RNA was denatured by formaldehyde, run on 1% agarose gels in 20 mM 191 
phosphate (pH 7.0) and 1% formaldehyde and blotted on Hybond N+ in 20xSSC. A DNA fragment 192 
covering the HBV genome was used as probe. DNA labeling and hybridization were performed with 193 
DIG High Prime DNA Labeling and Detection Starter Kit II (Roche). RNA sizes were estimated 194 
according to a molecular weight ladder (RNA Molecular Weight Marker I, DIG-labeled, Sigma-195 
Aldrich). 196 
Data access 197 
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Supplementary materials are accessible at 198 
http://gerg.gsc.riken.jp/JVI2016/SupplementaryMaterials.pdf. CAGE data for human HCC samples 199 
were released in the NCBI database of Genotypes and Phenotypes (dbGaP; 200 
http://www.ncbi.nlm.nih.gov/gap/) under accession number phs000885.v1.p1. CAGE data for human 201 
blood samples were released in the NBDC human database (http://humandbs.biosciencedbc.jp/en/) 202 
under hum0050. CAGE data for HBV model systems were released in the Gene Expression Omnibus 203 
(GEO; http://www.ncbi.nlm.nih.gov/geo/) under accession number GSE84186. 204 
 205 
 206 
207 
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RESULTS AND DISCUSSION 208 
Variable expression of HBV transcripts in human livers and HCC 209 
We have recently described CAGE analysis of human transcriptome in HCC and non-tumor 210 
livers (21). Among analyzed cases, sixteen pairs of tumor (T) and non-tumor (NT) liver samples from 211 
HBV-positive HCC patients were selected for further studies of the HBV transcriptome (Tables 1 and 212 
S1). Searching for CAGE tags that did not match human sequences, we identified a total of 376,770 213 
tags that were mapped on the HBV genome using 16 representative HBV sequences curated by 214 
HBVdb (25) (Table S2). Sequences from other viruses could not be found.  HBV transcripts were 215 
detected in 30 out of 32 samples with 1 tag per million (tpm) threshold, but not in HCV-associated 216 
samples used as controls. Expression levels of total HBV transcripts were highly variable in different 217 
samples from as low as TATA-box binding protein (TBP) (median=5.3 tpm) to as high as beta-actin 218 
(ACTB) (median=1,128 tpm) (Fig. 1A). A high variability was observed also between T and NT 219 
samples from the same individual; for example, the expression value is 781 tpm in sample 8T and 220 
only 2.7 tpm in 8NT, the matched non-tumor (Fig. 1B). It should be noted that most patients received 221 
antiviral treatment at the time of tumor resection (Table 1), which might account for low level HBV 222 
transcription in a majority of samples, as previously reported (34). We then determined the closest 223 
genotype for each sample based on the counts of tags mapped on 16 HBV genomes across 8 major 224 
genotypes (25). The determined genotypes with the highest tag counts were mostly A and D, known 225 
to be prevalent in Europe (Table 1). Despite a number of ambiguous sequence positions in the tags, 226 
we found evidence for different genotypes in four T/NT pairs, probably reflecting intergenotype dual 227 
infection of these patients as already reported in other studies (35). 228 
We identified 17 robust TSSs (CAGE peaks) supported by at least 100 raw tag counts in total 229 
and expressed at least in 10 samples, of which 6 peaks supported by more than 1000 raw tags were 230 
referred to as major peaks (Fig. 1C). Several known TSSs were correctly identified as major peaks by 231 
this method including preS1 (peak #1), preS2/S (peak #2), and pgRNA (peak #16). The TSS positions 232 
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were either highly specific, especially for pgRNA at position 1818, 4 bp downstream of the preC start 233 
codon (7) (Fig. 2A), or scattered over several positions as exemplified by the basal core promoter 234 
(BCP) region between positions 1740 and 1785, where the preC RNA TSS has been mapped 235 
previously (8, 10). In this study, the only recurrent TSS position in the BCP region was localized at 236 
nucleotides 1745-1746 (Fig. 2B). In a large majority of T and NT samples, pgRNA levels were >10-237 
fold higher than other transcripts in the BCP. As expected, preS/S transcripts and pgRNA were 238 
predominant RNAs in all samples (Fig. 2C), although the percentages varied greatly between 239 
individual cases. Among the minor peaks, two antisense transcripts that could represent ncRNAs were 240 
detected at low levels of expression (see Fig. 1C). One of them started in the preC region, close to the 241 
core promoter (peak #17) and the second, transcribed from the middle of the X gene (peak #12) and 242 
detected in 14 samples, was previously reported as a minor non-polyadenylated transcript (36). Note 243 
that CAGE can capture both polyA plus and minus transcripts by using random primers. These minor 244 
anti-sense transcripts might be involved in the regulation of the neighboring promoters. 245 
 246 
Heterogeneous promoter usage for the S and X genes 247 
It is known that two independent promoters are responsible for producing three forms of the 248 
surface proteins (large, middle, and small). The first one, called the preS1 promoter, characterized by 249 
a canonical TATA box, is located upstream of the first start codon. The other one, called the preS/S 250 
promoter, is located in the preS1 region and it is devoid of a TATA box, which enables to generate 251 
two types of mRNAs, initiated either upstream or downstream of the preS2 start codon, and giving 252 
rise to the middle protein or the small protein using the third start codon (11). In addition to the preS1 253 
promoter (peak #1) and the preS2/S promoter (peak #2), we identified an extra major promoter (peak 254 
#3) for the small protein (Fig. 3A). This potential novel promoter is characterized by an enriched TSS 255 
at position 111, immediately downstream of the preS2/S promoter, and it gives broad but weak signals 256 
(Fig. 3B). The expression level of this promoter is as high as the preS1 promoter, but much lower than 257 
the preS2/S promoter except for 1T and 2NT samples (Fig. 3A). Due to the predominant expression of 258 
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the preS2/S promoter in a large majority of samples, the ratio of middle to small surface proteins 259 
depends on the TSS usage within this promoter. As reported in previous studies, we observed 260 
heterogeneous 5’ ends distributed upstream and downstream of the ATG, but more importantly these 261 
TSSs are not equally used in different samples. Interestingly, our quantitative TSS mapping shows at 262 
least three distinct patterns of the TSS usage depending, at least in part, on the HBV genotype. The 263 
first group (genotype D) has the most frequent start site at nucleotide 3190 with weaker signals at 264 
nucleotides 3212, 5, 7, and 18. The second group (genotype A) has the strongest signal at nucleotide 265 
3212 with a weaker signal at 3190, and the third group (mostly genotype E) has the strongest signal at 266 
nucleotides 5 or 7 with weaker signals at 3190 and 3212 (Fig. 3B). 267 
Unlike the S gene, the X gene is widely believed to produce a single form of protein (17 kDa 268 
X protein or HBx) translated from a 0.7 kb mRNA. This protein is required for HBV replication in 269 
vivo and functions as a broad-range transactivator that stimulates expression of viral and cellular 270 
genes (37-39). We identified a faint peak upstream of the first ATG of the X gene (peak #10, Fig. 4A), 271 
corresponding to a part of the canonical X promoter (9). Surprisingly, we identified a higher peak 272 
between the first and the second ATG (peak #11), which shows moderate expression levels in a subset 273 
of samples (Fig. 4A). The transcription starts preferentially at nucleotide 1524 in tumors and non-274 
tumor livers (Fig. 4B). Note that although the cap selectivity of the CAGE technology is very high 275 
(333~625 fold enrichment for capped RNAs (26)), it is still possible to have artificial peaks on 276 
cleavage hot-spots produced by massive amounts of site-specific cleavage events. Nevertheless, a 277 
recent study using covalently closed circular DNA (cccDNA) ChIP-Seq approach has shown two 278 
distinct peaks of active promoter marks (H3K4me3, H3K27ac, and H3K122ac) within the X gene 279 
body, especially prominent in HBV-infected primary human hepatocytes and HBV-positive liver 280 
tissues (40). The second histone modification peak located at the middle of the X gene might be 281 
associated with the new TSS detected here. Moreover, analysis of the conservation of X gene in-frame 282 
ATGs using 6,949 nucleotide sequences across 8 genotypes showed that the second ATG is as well 283 
conserved as the first ATG (99.6% for both), whereas the third ATG is slightly less conserved 284 
(94.0%). It has been shown previously that the X gene is able to produce shorter peptides, which are 285 
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translated from the second and the third in-frame start codons in cell lines, and can function as 286 
transactivators in a similar manner as full-length HBx (41, 42). Collectively, these data indicate that 287 
the potential novel transcript evidenced by CAGE might give rise to a shorter HBx protein retaining 288 
transactivator function to regulate viral and host genes. 289 
Comparison of TSS usage between HCCs and non-tumor livers 290 
HBV expression levels were highly heterogeneous in HCC samples, with total counts about 291 
2-fold lower than non-tumor liver samples (no significant difference, p= 0.7437, Wilcoxon rank sum 292 
test). These data are in agreement with the notion that HBV transcription and replication are reduced 293 
in tumors compared to liver. As shown in Table S3, predominant TSSs in HCCs were found for the 294 
preS2/S promoter (peak #2), followed by the core (peak #16), preS1 (peak #1) and S promoters (peak 295 
#11). While average activity of the preS2/S promoter was similar in T and NT livers, average 296 
transcription from the preS1, core and X promoters was about 4-fold lower in HCCs. This might 297 
reflect the strict requirement of these promoters for liver-enriched transcription factors, contrasting 298 
with the preS2/S promoter regulation by ubiquitous factors (43). Presently, it is not possible to 299 
determine whether viral RNAs detected in HCC are produced from integrated HBV sequences or 300 
from episomal cccDNA. However, TSS positions in HCC were almost identical to those in NT livers, 301 
and we observed in most tumors a robust pgRNA TSS at position 1818, a region frequently disturbed 302 
by host-viral junctions upon HBV integration (44), suggesting that transcription might occur from the 303 
HBV cccDNA as well as integrated HBV sequences, which might contribute to HBV recurrence after 304 
liver transplantation (45). 305 
HBV transcriptome in blood 306 
The HBV genome is generally considered to be transcribed only in liver, but viral RNAs are 307 
frequently found in the serum of HBV-infected patients (46). To better characterize these HBV RNA 308 
species, we sequenced new CAGE libraries for 8 whole blood samples derived from HBV genotype C 309 
positive patients, independent of the first patient group (Fig. 5A). CAGE tags aligned to the HBV 310 
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genome (CQ358158.1: a representative genotype C) were detected from all samples, ranging from 40 311 
to 2500 tpm. The level of transcripts is significantly correlated with the level of HBsAg in blood 312 
(Spearman's correlation coefficient=0.762 and P=0.037) (Fig. 5B). Comparison of TSS positions with 313 
the 17 peaks identified in liver tissues showed a high prevalence of TSS at position 1818, whereas few 314 
tags were mapped to the S promoters (Figs. 5C and 5D). This major start site is consistent with the 315 
pgRNA TSS found in tumor and liver samples (see Fig. 2A) as well as in previous studies (7). Thus, 316 
the predominance of pgRNA in blood samples suggests that immature capsids, in which HBV DNA 317 
replication has not been completed, might be released from liver into blood, as already observed in 318 
several reports (46-49). We have to consider another possibility, where CAGE captures the capped 5’ 319 
end of the pgRNA that survives as a short RNA fragment attached to the +polarity DNA strand in 320 
HBV virions, although a majority of DNAs hybridized with short 5’ RNA is likely to be removed in 321 
the process of RNA purification and CAGE library preparation. 322 
 323 
HBV transcriptome in experimental model systems 324 
To determine whether in HBV activities might be different between clinical and experimental 325 
conditions, we prepared and sequenced CAGE libraries for 4 experimental HBV model systems: (1) 326 
the HepG2.2.15 cell line, (2) primary human hepatocytes (PHH) infected with HBV (3) the HepAD38 327 
cell line (4) mouse liver transduced with AAV-HBV (Table S4). PHH is a model in which HBV is 328 
transcribed from cccDNAs whereas in the other three models, genes are mainly transcribed from 329 
integrated HBV genomes, although in HepAD38 cells, transcription might also occur from cccDNA 330 
that is made by nuclear re-import of encapsidated RCDNA (50). We identified HBV transcripts from 331 
all samples, ranging from 500 to 7,000 tpm (Fig. 6A), which is comparable with mean expressions of 332 
523 tpm for tumors and 704 tpm for non-tumors. We calculated expression values for the predefined 333 
17 TSSs (Table S5). While pgRNA and preS/S RNAs are the major transcripts in all models, major 334 
differences between their relative levels are seen among the models. For example, the expression of 335 
preS/S is as high as pgRNA in the mouse AAV-HBV model whereas the expression of pgRNA is 336 
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predominant in the other models (Fig. 6A). We then independently performed peak calling for the 337 
model systems using Paraclu with the same parameters used for the clinical samples. We identified 15 338 
peaks, 10 of which overlap with the clinical peaks (5 out of 6 major peaks and 5 out of 11 minor 339 
peaks), indicating that a majority of TSS peaks are shared in clinical and experimental conditions (Fig. 340 
1C and Table S6). On the other hand, a major difference was found in the basal core promoter region, 341 
in which the major peak #15 was not detected in the model systems, instead clear signals were 342 
detected between 1780 and 1800 bp (Fig. 6B), corresponding to previous report of the preC RNA start 343 
site (10). The relative expression of the 1780-1800 bp region among model systems is similar to the 344 
PreS/S (Peak #2), where the AAV-HBV model is the highest. The X promoter also shows a different 345 
pattern from the clinical condition. In addition to peaks #10 and #11, another broad peak was detected 346 
around 1250 bp, upstream of the 1st ATG, which can contribute to the full-length X protein (Fig. 6C). 347 
This suggests that HBV might use different promoters for two sizes of X proteins in different 348 
conditions, although functional analysis such as reporter assays is essential for further understanding 349 
of the promoter usage. The PreS/S promoter shows consistent pattern with the clinical peaks for 350 
genotype D with some variable signals at position 7 bp (Fig. 6D). Finally, we analyzed HBV RNA by 351 
Northern blotting in two experimental models including HepAD38 cells and mouse liver transduced 352 
with AAV-HBV to visualize major HBV transcripts. The data showing important differences in the 353 
relative levels of major transcripts (pgRNA and preS2/S RNA) between the two systems are in 354 
complete agreement with the CAGE data (Fig. 6E). 355 
 356 
CONCLUSION 357 
In this study, we employed CAGE analysis to investigate the HBV transcriptome in non-358 
tumor liver, HCC, and blood from HBV positive patients, as well as in four experimental HBV 359 
replication systems. This approach provided extensive and accurate positioning of all HBV TSSs as 360 
well as quantitative evaluation of relative expression levels in the clinical setting. We also provide 361 
evidence for HBV transcriptional activity in tumor cells, although transcription template (episomal or 362 
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integrated HBV sequences) cannot be ascertained by current technologies. A comprehensive and 363 
quantitative map of HBV transcripts in human tissues has not been described so far using 364 
conventional technologies, due to the compact structure of the HBV genome and the overlap of 365 
different open reading frames. In this paper, transcription from the four well-studied promoters (core, 366 
preS1, S, and X promoters) was correctly detected in the regions described in previous studies, with 367 
detailed information on relative TSS usage in the S and core promoter regions. Additionally, 11 novel 368 
TSSs were discovered. One novel major TSS is located in the X gene body between the first and 369 
second start codons. Because of the high reproducibility of this transcription peak, its higher 370 
expression level compared to the canonical X transcript in nearly all clinical samples, and the strong 371 
conservation of the second ATG, we propose this transcript as a candidate mRNA that encodes a 372 
shorter form of the X protein. It has been reported that this short X protein might be endowed with 373 
transactivator functions similar to full-length HBx (42). We also detected minor, recurrent anti-sense 374 
TSSs in the core promoter and the X gene, which might represent ncRNAs implicated in the 375 
regulation of HBV transcription and could be used for therapeutic approaches based on selective 376 
inhibition of HBV transcription and replication. Current therapeutic regimens including nucleos(t)ide 377 
analogs such as lamivudine potently inhibit viral replication, but are not capable of eliminating the 378 
virus or controlling infection on the long-term after drug withdrawal, because of frequent persistence 379 
of the HBV cccDNA within hepatocytes. Therefore, a potential therapeutic strategy to eradicate HBV 380 
could be to silence and eliminate cccDNA from infected cells. In this context, our study offers new 381 
tools for the characterization of HBV transcriptional responses in experimental setting. 382 
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FIGURE LEGENDS 618 
 619 
Figure 1. Quantification of HBV transcripts and comprehensive TSS map of HBV in chronically 620 
infected non-tumor livers and HCC A. Distribution of expression values for HBV transcripts and 621 
housekeeping genes in 15 tumor and 15 NT samples (sample #3 is excluded). The TATA-box binding 622 
protein (TBP) and beta-actin (ACTB) genes are representatives of moderately and highly expressed 623 
genes, respectively. Expression data are derived from the same 15 HCC patients. B. Relative HBV 624 
expression levels between tumor and matched non-tumor samples. Relative value of 0.5 indicates that 625 
HBV expression levels are the same in T and NT. Samples are sorted by tumor ratios. C. Distribution 626 
of detected CAGE peaks in the HBV genome. Large and small arrows on the outer circle indicate 627 
major CAGE peaks supported by >1,000 tags and minor peaks supported by 100~1,000 tags. Arrows 628 
inside the circle represent open reading frames for four HBV genes. Genomic coordinates in the right 629 
panel correspond to the representative genome (GQ358158.1), where the EcoR1 site is the first 630 
position (+1). “Model” in the tables indicates whether the peak is present in HBV replication model 631 
systems (see Fig. 6 and Table S6). 632 
 633 
Figure 2. TSSs distribution in the basal core promoter (BCP) region in non-tumor liver and 634 
HCC. A. Major peaks for preC and pgRNA, showing a predominant peak for pgRNA (peak #16) at 635 
position 1818, and scattered minor peaks over the BCP region. The scale shown at the right represents 636 
the maximal tag counts in each sample. B. Recurrent TSS for PreC/C RNA (peak #15). TSS shape 637 
from pooled samples is shown in the lower panel. C. Relative expression levels of the preS/S 638 
transcripts, pgRNA, and others in T (left panel) and NT samples (right panel). 639 
 640 
Figure 3. TSSs in the S region at single nucleotide resolution. A. The major peaks for the S region. 641 
The peak #1 is located upstream of the preS1 ORF whereas peaks #2 and #3 are located inside preS1 642 
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and preS2 ORFs. Relative expression values of three major peaks in T and NT samples are shown 643 
(Yellow: #1, Green: #2, Red: #3, and Blue: other minor peaks, found only in some samples such as 1T 644 
and 2NT). Expression values of Peaks #2 and #3 are shown in the log scale. B. TSSs distribution 645 
inside the peaks #2 and #3 at single nucleotide resolution. The preS2 ATG is shown as a vertical grey 646 
bar. Red bars upstream of the preS2 ATG represent TSSs for the middle protein whereas blue bars 647 
downstream of the ATG represent TSSs for the small protein. 648 
 649 
Figure 4. TSSs in the X gene region at single nucleotide resolution. A. Expression values of the 650 
new TSS located inside of the X gene (peak #11) and the canonical TSS upstream of the X gene (peak 651 
#10). B. TSSs distribution between the first and second ATGs of the X gene for 6 tumors and 7 non-652 
tumors in which expression values are > 1 tpm. Conservations of the three ATG among 6,949 653 
nucleotide sequences from different HBV genotypes are 99.6% (6,919 out of 6,949) 99.6% (6,919 out 654 
of 6,949), and 94.0% (6,534 out of 6,949). 655 
 656 
Figure 5. Identification and quantification of HBV transcripts in blood. A. A list of human blood 657 
samples analyzed by CAGE. Samples were collected from male genotype C positive patients with 658 
various HBsAg levels. B. Association between RNA and HBsAg levels in blood. Each dot represents 659 
one blood sample. Both X and Y-axes are shown in log-scale. C. Relative expression of detected 660 
RNAs in blood. About 87~95% of tags are mapped within the pgRNA peak. Outside indicates the 661 
tags mapped outside of all 17 HBV peaks detected in the liver transcriptome. D. Transcription start 662 
sites of the pgRNA in blood. The scale of y axis is fit to the raw tag counts of each sample. 663 
 664 
Figure 6. Identification and quantification of HBV transcripts in model systems. A. Expression 665 
values of total HBV, pgRNA (Peak #16), PreS/S (Peak #2), and the new TSS inside of the X gene 666 
(Peak #11). B. TSSs distribution in the basal core promoter region. Detailed CAGE signals and 667 
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expression values between 1780 to 1800 bp are shown in the left panel. C. TSSs distribution in the X 668 
promoter region upstream and downstream of the 1st start codon. D. TSSs distribution in the PreS/S 669 
promoter region. E. Northern blot analysis of HBV RNA. Total RNA (20 µg) from HepAD38 cells 670 
and from mouse livers transduced with either AAV-HBV vector (AAV-HBV) or control AAV-GFP 671 
vector (control) was analyzed by Northern blotting. For HepAD38 cells, a shorter exposure is shown 672 
in the second lane. Sizes of major transcripts are indicated on the right. 673 
 674 
 675 
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Table 1. Clinical samples with serological HBV markers 
ID gender age Predicted 
Genotype 
 (T) 
Predicted 
Genotype
 (NT) 
HBsAg HBcAg/ HBeAg/ anti-HBe antiviral treatment 
1  male 47  A   G  positive negative Lamivudine and Adefovir dipivoxil 
2  male 62  E   A  positive anti-HBe positive Tenofovir 
3  male 56 - - negative anti-HBc positive no treatment 
4  male 59  D   D  negative anti-HBc positive no treatment 
5  male 73  D   D  positive HBeAg positive Adefovir dipivoxil 
6  female 56  D   A  positive NA Lamivudine 
7  male 54  D   E  NA NA NA 
8  male 38  A   A  positive anti-HBc, anti-HBe positive Lamivudine 
9  male 49  D   D  positive anti-HBc, anti-HBe positive no treatment 
10  male 60  E   E  positive HBeAg positive Adefovir dipivoxil 
11  male 47  E   E  positive NA Lamivudine 
12  male 58  C   C  positive HBeAg positive Lamivudine 
13  male 73  D   D  positive NA NA 
14  male 72  A   A  negative anti-HBc positive no treatment 
15  male 55  A   A  positive HBcAg positive Lamivudine, Adefovir dipivoxil and 
Tenofovir 
16  male 66  C   C  positive anti-HBc positive Lamivudine and Adefovir dipivoxil 
The HBcAg, HBcAg, HBeAg, and anti-HBe were measured in the serum. NA indicates data not available. 
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